Anticoagulation Therapy in Patients with Non-Valvular Atrial Fibrillation: Effects of Apixaban
Objective of the Review: To describe data about Apixaban obtained from some subanalyses performed in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) randomized clinical study, which can be useful for practitioners when choosing use new oral anticoagulants for long-term prevention of ischemic events in patients with atrial fibrillation (AF). Key Points: This paper analyzes the advantages of Apixaban over warfarin in terms of efficacy and safety in patients with non-valvular AF in different clinical settings (advanced age, renal dyfunction, cardiovascular comorbidity, concomitant treatments, and high risk of hemorrhage). This analysis is based on the results of the subanalyses performed in the ARISTOTLE clinical study. Conclusion: The results of numerous subanalyses performed in the ARISTOTLE international randomized study suggest that, due to a unique combination of its efficacy and safety, Apixaban (Eliquis) can be recommended for long-term anticoagulation therapy in patients with AF and a wide range of concomitant disorders and clinical conditions that increase the risk of thrombotic, ischemic, and hemorrhagic events.